The cryoSPHERE MAX device, part of AtriCure’s cryoNB therapy, cuts ablation time by 50% per nerve, reducing it to 60 seconds.
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves ...
simpler heart ablation in cardiac surgeries with advanced radiofrequency technology. MASON, Ohio, October 08, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and ...
AtriCure's FDA-approved solutions include the Isolator Synergy Ablation System for persistent Afib, the AtriClip for left atrial appendage management, and Hybrid AF Therapy, a minimally invasive ...
AtriCure Inc is an innovator in surgical treatments ... Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety ...
JPMorgan analyst Lilia-Celine Lozada assumed coverage of AtriCure (ATRC) with an Overweight rating and $40 price target With numbers reset and competitive headwinds not materializing as feared ...
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves ...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio ...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management ...